Advanced Search

 

Study ID Status Title Patient Level Data
205202 Completed A Method Development Clinical Study to Investigate the Efficacy of the Different Frequencies of Use of a Denture Cleanser
205206 Not yet recruiting Evaluation of vaccine efficacy (VE) against individual non-vaccine carcinogenic HPV types and related disease among women in a TVC-naïve cohort: a pooling effort using data from HPV-008 and HPV-009
205212 Completed Short Term Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief from Dentinal Hypersensitivity
205213 Completed A Phase 2, open-label, controlled, multi-center extension study to evaluate 4-year antibody persistence and booster response following MenABCWY vaccination in healthy adolescents and young adults who previously participated in studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)
205214 Active, Not Recruiting A Phase 3, Open-label, Multicenter Study to Evaluate Long-term Immunogenicity and Boostability of Immune Responses in Adults who Received Different Primary Vaccination Regimens of Pre-exposure Prophylaxis with Purified Chick-Embryo Cell Rabies Vaccine Administered Concomitantly or Separately from a Japanese Encephalitis Vaccine.
205215 Completed A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of GSK Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to GSK Meningococcal group B vaccine, in Healthy Adolescents
205218 Completed A Phase 3b, Open Label, Controlled, Multi-Center, Extension Study to Assess the Persistence of Bactericidal Activity at 4 to 7.5 Years After Two Dose Primary Series of GlaxoSmithKline Biologicals Meningococcal B Recombinant Vaccine and the Response to a Third Dose in Adolescents and Young Adult Subjects who Previously Participated in Parent Studies V72_41 (NCT01423084) and V72P10 (NCT00661713), Compared to Naïve Healthy Controls
205219 Completed A Phase 1 Randomized, Observer Blind, Placebo Controlled, Dosage-Escalation Single Center Study to Evaluate the Safety and Immunogenicity of an RSV Fusion Glycoprotein (F) Subunit Vaccine in Healthy Adults
205220 Completed A Phase II, Randomized, Comparative, Observer-Blind, Multi-Center Study evaluating the Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine in Healthy Non-Pregnant Women aged 18 to 40 Years
205232 Completed A Phase 2b, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of the 3rd Dose of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.
205235 Completed A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women
205240 Completed A Phase 3b, Open-Label, Randomized, Multicenter Study to Assess the Safety and Immunogenicity of Novartis Meningococcal group B Vaccine When Administered Concomitantly with Novartis MenACWY Conjugate Vaccine to Healthy Infants
205249 Completed A Phase 3, Open Label, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Meningococcal B Recombinant Vaccine When Administered concomitantly with Routine Vaccines to Healthy Infants in Taiwan.
205255 Not yet recruiting A 2-year follow-up study of a longitudinal, multicentre, historical-prospective, observational pharmacoepidemiological cohort of pretreated HIV-1-infected patients with treatment failure and initiating treatment with dolutegravir, in France
205335 Completed A phase IV, open-label, single-center study to evaluate long term immunogenicity up to 10 years after the first booster immunization with Tick Borne Encephalitis vaccine in adults who received 1 of 3 different primary vaccination schedules
205336 Active, not recruiting A Phase IV, Open-Label, Multi-Center Study to Evaluate the Safety and the 1-year Persistence of Antibody Response Among Children Who Received 4 Doses of the GSK MenACWY Conjugate Vaccine at 2, 4, 6 and 12 Months of Age in South Korea
205341 Recruiting A Multicenter Post Marketing Surveillance Study to monitor the safety of Novartis Meningococcal ACWY conjugate vaccine(MenACWY-CRM) administered according to the prescribing information to healthy subjects from 2 months to 55 years of age in the Republic of South Korea.
205352 Recruiting A Phase 3b, Controlled, Open-Label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Single Dose of GlaxoSmithKline’s Meningococcal ACWY Conjugate Vaccine (Menveo), Administered to Healthy Individuals 15 through 55 years of age, approximately 4-6 years after primary ACWY vaccination
205369 Completed Impact of rotavirus vaccination on hospital pressures at a large paediatric hospital in the UK: an ecological study
205421 Completed A Phase 2, Non-Randomized, Controlled, Open-Label, Parallel-Group, Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-pregnant Subjects.
205431 Withdrawn Determination of SPF, before and after immersion in water, for a cosmetic product at minimum of 3 subjects.
205432 Withdrawn Determination of SPF, before and after immersion in water, for a cosmetic product at minimum of 3 subjects
205433 Withdrawn Determination of SPF, before and after immersion in water, for a cosmetic product at minimum of 3 subjects.
205434 Not yet recruiting A comparative, open-label, randomized, and controlled clinical efficacy trial for preview evaluation of the skin oiliness control for three cosmetics products
205496 Active, Not Recruiting A Phase 1, Randomized, Observer-Blind, Dosage-Escalation Study to Evaluate the Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine Compared to Aluminium Hydroxide Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine in Healthy Adults (18-45 years of age).

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.